NCT06437639View on ClinicalTrials.gov

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

February 2, 2024

Conditions
Primary Open-Angle Glaucoma (POAG)
Interventions
DRUG

Mexidol

Neurocytoprotector

Trial Locations (1)

625026

Tyumen Scientific Center of the Russian Academy of Sciences, Tyumen

Sponsors

Lead Sponsor

Pharmasoft
All Listed Sponsors
lead

Pharmasoft

INDUSTRY

NCT06437639 - MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) | Biotech Hunter | Biotech Hunter